At XenoPort, we believe we can offer patients improved therapies to more effectively treat debilitating conditions or diseases. We focus our drug discovery efforts on medical conditions where we believe current drugs are not providing optimal therapeutic benefit. XenoPort is seeking partners who share our commitment to significantly impact patients' lives through improved treatment options.

Our strategy is to seek collaborations with leading pharmaceutical companies to accelerate development and commercialization of our product candidate pipeline at the appropriate time. We have licensed our lead product candidate, gabapentin enacarbil, to GlaxoSmithKline in the United States and Astellas Pharma Inc. in Japan and five Asian countries. In April 2011, the FDA approved this product, which is now known as Horizant (gabapentin enacarbil) Extended-Release Tablets in the United States. We are currently awaiting regulatory approval in Japan for this product candidate.

XenoPort has experience forming and operating strategic alliances, ranging from enabling technologies and manufacturing, to full development and commercialization agreements. For further information, please contact XenoPort Business Development BD@xenoport.com.